HR-9946-119
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, Armed Services, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Nikema Williams (D-GA)
What it does
This bill would require Medicare Advantage, Medicaid, CHIP, TRICARE, the VA health system, and Indian Health Service programs to cover screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia without any copayments or other cost-sharing. Coverage would generally align with tests already required to be covered without cost-sharing under private insurance preventive services rules, with most changes effective within one year of enactment.
Who benefits
Medicare Advantage enrollees, Medicaid and CHIP beneficiaries, active-duty and retired military members and their families on TRICARE, veterans enrolled in VA care, and Indians receiving care through the Indian Health Service or Urban Indian Organizations who would no longer pay out-of-pocket for these specific STI tests; public health advocates who argue routine testing reduces disease transmission.
Who is hurt
Federal and state government budgets that fund Medicaid, CHIP, TRICARE, VA, and IHS would bear increased costs from eliminated cost-sharing and expanded utilization; state Medicaid and CHIP agencies would face administrative and systems-update burdens to implement the new coverage requirement, particularly states needing legislative changes; Medicare Advantage plans and TRICARE contractors would see modestly higher claims costs, which could be passed through in premiums over time.
Supporters argue
Supporters argue that cost-sharing is a well-documented barrier to STI testing, and that removing copays for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia screening would increase early detection and treatment, reducing long-term transmission and downstream medical costs. They contend the bill simply extends the no-cost preventive testing standard already required for private insurance under the Affordable Care Act to public programs like Medicaid, TRICARE, and the VA, closing a coverage gap that disproportionately affects lower-income, military, veteran, and Indian populations.
Opponents argue
Opponents argue that mandating first-dollar coverage across five federal health systems simultaneously imposes new administrative and fiscal burdens on state Medicaid programs, the Department of Defense, VA, and Indian Health Service without a clear funding offset identified in the bill. They contend that expanding cost-sharing exemptions incrementally, rather than through a single sweeping mandate spanning multiple agencies and jurisdictions, would allow better assessment of true implementation costs and avoid straining already resource-constrained systems like IHS.